$SRPT

If you lost money shorting TSLA put whatever you have left in $srpt to make up your loss. You'll thank me in 2 weeks.

$srpt @EvenWangMD any comments from Sarepta ??https://twitter.com/mauriceontw/status/1224772472387657728 …

$srpt Curious how the Integration would go if there ever was a Buyer for all but Roche territory. Any ideas if a nice transition would be possible if we were split between 2 Behemoths? Hoping Roche is now debating to counter an Offer that Sarepta may have received. Dreaming.

I dream of a day where $srpt shorts will burn like TSLA shorts, I have a dream.

$SRPT Going into Q2 call we were at $142 and 1 yr from uD data...6+ mos away from uD manu, LGMD high dose, CMT, Mendell pub, PPMO data...and concerned of cash raise. Now we're at $115, same 1 yr from uD data, LGMD, CMT, Mendell/PPMO on horizon and Roche deal. Makes sense.

Short sale volume(not short interest) for $ADRO on 2020-01-31 is 54%. http://shortvolumes.com/?t=ADRO  $CHRS 54% $AFMD 41% $SRPT 58%

$SRPT - Sarepta Therapeutics, Inc. And Arrowhead Pharmaceuticals Now Top-Ranked Biotech Stock Buys. https://staging.seekingalpha.com/article/4320715-sarepta-therapeutics-inc-and-arrowhead-pharmaceuticals-now-top-ranked-biotech-stock-buys?source=feed_f&utm_campaign=twitter_automated&utm_content=article&utm_medium=social&utm_source=twitter_automated …

$srpt Possibly there will be word on the LGMD2D biopsy results soon. The last patient in the 6 patient study was dosed 3/14/2019 and the biopsy was to be taken 180 days later.

They have two drugs on the market now, with a 3rd coming this year. Also Roche recently invested 1B+ in $SRPT gene therapy. A possible takeout candidate any day now. Good luck on the short.

$NVS $RHHBY $SRPT $AMGN: Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs: https://www.StockNewsWires.com/nvs-rhhby-srpt-amgn-roche-rhhby-2019-sales-solid-on-robust-show-by-new-drugs/ …

Baml $SRPT, Buy, PO $188): SRPT preannounced $100.1mn in Exondys sales in 4Q. Main driver DMD gene therapy finished dosing in Study 102, will begin commercial-supply study 301 by mid-2020. Reit. Buy as top pick for 1H20.

$SRPT when is ER?

Interesting $PFE comments on their 3 leading #genetherapy programs 1. Hem B think will be 1st in class $QURE 2. Hem A think have best in class profile $SGMO $BMRN 3. #DMD we've talked about that $SRPT $SLDB look to add 1 #genetherapy program every year or so (int & ext)

BAIRD $SRPT What does this mean for Sarepta? Nothing. Our view is that Dr. Unger’s CRL really just seeks to relitigate what has already been decided by the commissioner https://twitter.com/_B_I_O_T_E_C_H_/status/1220804619066118151 …